Get the Stockscreener App
17.17
1.27%
-0.22
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $17.17, with a volume of 19.92M.
It is down -1.27% in the last 24 hours and up +26.53% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$17.39
Open:
$17.3
24h Volume:
19.92M
Relative Volume:
1.75
Market Cap:
$20.00B
Revenue:
$14.29B
Net Income/Loss:
$-3.51B
P/E Ratio:
-5.8001
EPS:
-2.9603
Net Cash Flow:
$1.85B
1W Performance:
+14.16%
1M Performance:
+26.53%
6M Performance:
+69.66%
1Y Performance:
+88.89%
1-Day Range:
$16.65
$17.53
1-Week Range:
$14.82
$17.53
52-Week Range:
$8.19
$17.53
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.17 | 20.00B | 14.29B | -3.51B | 1.85B | -2.9603 |
TAK
Takeda Pharmaceutical Co Adr
|
16.46 | 52.00B | 29.85B | 776.90M | 4.35B | 0.2408 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.73 | 41.60B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.11 | 40.43B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
82.83 | 34.72B | 9.47B | 2.67B | 2.28B | 6.0218 |
UTHR
United Therapeutics Corp
|
564.94 | 23.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Earnings Call Highlights Profits, Pipeline Momentum - The Globe and Mail
HHS officials considered banning SSRI antidepressantsreport - Seeking Alpha
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Research Alert: CFRA Keeps Hold Opinion On Shares Of Viatris Inc. - Moomoo
Viatris gears up to report Q1 earnings: What's in the cards? - MSN
symbol__ Stock Quote Price and Forecast - CNN
Viatris CFO leaving Canonsburg pharma giant - MSN
Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com
Viatris: Q1 Earnings Snapshot - theheraldreview.com
Viatris Inc. Stock 12‑Month Price Target Raised to $17.25, Implies 1% Downside - TradingView
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference - BioSpace
VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance - TradingView
5-Day Rally Sends Viatris Stock Up 16% - Trefis
Viatris Stock Rockets 16% With 5-Day Winning Streak - Trefis
Viatris stock hits 52-week high at $16.63 By Investing.com - Investing.com Nigeria
Viatris Q1 2026 Earnings Call Transcript - MarketBeat
Assessing Viatris (VTRS) Valuation After Its Recent Share Price Rebound - Yahoo Finance
Viatris Inc. stock rises Thursday, outperforms market - MSN
Viatris (VTRS) Jumps As Targets Rise And Pipeline Delivers - timothysykes.com
Viatris Earnings: Stable Base Business and Pipeline Progression Mark a Solid Start to 2026 - Morningstar
Viatris (NASDAQ: VTRS) returns to profit as sales rise in Q1 2026 - Stock Titan
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China - sharewise.com
Viatris signals 2026 cash deployment of more than $2.5B while expecting Greater China mid- to high-single-digit growth - MSN
Viatris Releases Q1 2026 Financial Results - AlphaStreet
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
After Kicking Off 2026 Solidly, Viatris Looks to New Launches and Cost Savings for Long-term Growth - Morningstar
Viatris’ Turnaround Story Is Paying Off in the Stock - Finimize
Viatris Q1 2026 slides: earnings beat drives shares higher - Investing.com
Viatris reports Q1 adjusted EPS 59c, consensus 50c - TipRanks
Earnings call transcript: Viatris Q1 2026 beats earnings expectations - Investing.com
Viatris beats quarterly estimates on China strength, branded drug sales - TradingView
Earnings call transcript: Viatris Q1 2026 beats earnings expectations By Investing.com - Investing.com UK
Viatris stock hits 52-week high at $16.63 - Investing.com
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings - Yahoo Finance
Viatris stock rises after Q1 2026 beat (VTRS:NASDAQ) - Seeking Alpha
Viatris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Viatris Delivers Strong Q1 2026 Results, Reaffirms Guidance - TipRanks
Viatris Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-05-07 - Seeking Alpha
Viatris (VTRS) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
(VTRS) Viatris Expects 2026 Adjusted EPS Range $2.33$2.47, vs. FactSet Est of $2.44 - marketscreener.com
Viatris (NASDAQ:VTRS) Shares Rise as Q1 Earnings Top Estimates - ChartMill
Viatris Q1 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Guidance - marketscreener.com
Earnings Flash (VTRS) Viatris Inc. Posts Q1 Adjusted EPS $0.59 per Share, vs. FactSet Est of $0.50 - marketscreener.com
Earnings Flash (VTRS) Viatris Inc. Reports Q1 Revenue $3.52B, vs. FactSet Est of $3.36B - marketscreener.com
Viatris shares slip 3% despite earnings beat on soft guidance By Investing.com - Investing.com Canada
Viatris Reports First-Quarter 2026 Financial Results - Viatris Newsroom
Viatris : VTRS Q1 2026 Non-GAAP ReconciliationsFINAL - marketscreener.com
Viatris : VTRS Q1 2026 Earnings PresentationFINAL - marketscreener.com
Viatris’s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue - Yahoo Finance
Earnings Flash (VTRS) Viatris Inc. Posts Q1 Adjusted EPS $0.59 per Share, Vs. FactSet Est of $0.50 - Moomoo
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):